Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and laboratory characteristics of patients stratified by renal function

From: Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function

  Group I
(N = 189)
Group II
(N = 222)
Group III
(N = 202)
p
Age (years) 60.0 ± 11.7 66.8 ± 11.6 52.4 ± 14.9 0.000**
Male 57 (30.5 %) 136 (61.3 %) 117 (58.2 %) 0.000***
Caucasian 105 (56.1 %) 145 (65.9 %) 138 (68.9 %) 0.000***
BMI (kg/cm2) 30.3 ± 6.2 28.6 ± 5.1 25.2 ± 2.6 0.000**
Waist circumference (cm) 98.3 ± 13.9 101.9 ± 13.5 95.6 ± 10.8a 0.004*
Diabetes mellitus 59 (32.6 %) 118 (53.4 %) 65 (32.5 %) 0.000***
Metabolic Syndrome 118 (64.1 %) 158 (71.8 %) 146 (73.0 %) 0.000***
Cardiovascular Disease 44 (24.6 %) 91 (41.9 %) 86 (43.7 %) <.000***
o Cerebrovascular disease 20 (11.2 %) 26 (12.0 %) 21 (10.7 %) 0.912***
o Coronary disease 17 (9.5 %) 51 (23.5 %) 44 (22.3 %) 0.001***
o Peripheral vascular disease 11 (6.1 %) 18.9 (41.0 %) 46 (23.4 %) 0.000***
o Congestive heart failure 17 (9.5 %) 33 (15.3 %) 31 (15.7 %) 0.000***
Statin use 77/181 (40.7 %) 125/222 (54.3 %) 107/200 (53.2 %) 0.017***
Cholesterol(mM) 4.78 ± 0.93 4.65 ± 1.12 3.72 ± 1.00a.b 0.000*
HDL-C(mM) 1.27 ± 0.34 1.16 ± 0.33c 0.99 ± 0.37 a.b 0.000*
LDL-C(mM) 2.78 ± 0.82 2.64 ± 0.97 1.89 ± 0.74a.b 0.000*
Triglycerides(mM) 1.61 ± 0.90 1.80 ± 0.98 1.91 ± 1.31 0.023**
Creatinine(μM) 73.4 ± 15.9 175.0 ± 69.8 930.8 ± 284.6 0.000**
ADMA (μM) 0.48 ± 0.12 0.75 ± 0.31a 1.34 ± 0.90 0.000**
CRP (mg/dL) 0.49 ± 0.73 0.62 ± 0.83 1.47 ± 3.78 0.004**
  1. *ANOVA, **Kruskal-Wallis-one way- ANOVA, ***Pearson chi-square
  2. By post hoc Bonferroni test: agroups III and II, bgroups III and I, cgroups II and I